U.S. markets closed

Telesis Bio, Inc. (TBIO)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
0.3213+0.0017 (+0.53%)
Al cierre: 04:00PM EDT
0.3154 -0.01 (-1.84%)
Fuera de horario: 07:07PM EDT

Telesis Bio, Inc.

10431 Wateridge Circle
Suite 150
San Diego, CA 92121-2993
United States
858 228 4115
https://telesisbio.com

Sector(es)Healthcare
IndustriaMedical Devices
Empleados a tiempo completo137

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Todd R. Nelson MBA, Ph.D.Founder & Director924.38kN/D1967
Mr. Daniel G. Gibson Ph.D.Chief Technology Officer590.37kN/D1977
Mr. Robert H. CutlerChief Legal Officer568.58kN/D1968
Mr. Eric EsserPresident, CEO, COO & DirectorN/DN/D1969
Mr. William J. KullbackChief Financial OfficerN/DN/D1960
Ms. Jen CarrollVice President of Investor RelationsN/DN/DN/D
Mr. Decky Goodrich M.B.A.Senior Vice President of Corporate DevelopmentN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Telesis Bio, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.